Trial Details
COMPLETEDBasic Information
| Clinical ID | c1622 |
|---|---|
| Identifier | NCT01745770 |
| Trial Title | TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC) |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Active Ulcerative Colitis |
| Interventions | DRUG: Mesalazine - TID 1000 mg|DRUG: Mesalazine - TID 2x 500 mg |
Participant Information
| Sponsor | Dr. Falk Pharma GmbH |
|---|---|
| City | Frankfurt |
| Country/Region | Germany |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2025-01-13 |
|---|---|
| Primary Completion Date | 2025-03-15 |
| Completion Date | 2025-06-15 |